David Owen Williams, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug-Eluting Stents | 13 | 2020 | 753 | 1.460 |
Why?
|
Angioplasty, Balloon, Coronary | 17 | 2016 | 1873 | 1.390 |
Why?
|
Coronary Restenosis | 7 | 2016 | 424 | 0.990 |
Why?
|
Stents | 13 | 2016 | 3282 | 0.870 |
Why?
|
Coronary Artery Disease | 11 | 2020 | 6486 | 0.830 |
Why?
|
Cardiology | 3 | 2018 | 1668 | 0.730 |
Why?
|
Myocardial Revascularization | 5 | 2020 | 841 | 0.720 |
Why?
|
Coronary Artery Bypass | 10 | 2020 | 2288 | 0.720 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 6 | 2014 | 314 | 0.710 |
Why?
|
Radial Artery | 1 | 2021 | 194 | 0.680 |
Why?
|
Coronary Stenosis | 5 | 2011 | 834 | 0.540 |
Why?
|
Coronary Occlusion | 1 | 2017 | 304 | 0.470 |
Why?
|
Coronary Disease | 5 | 2020 | 6077 | 0.470 |
Why?
|
Brachytherapy | 3 | 2016 | 1248 | 0.450 |
Why?
|
Specialization | 1 | 2018 | 776 | 0.440 |
Why?
|
Career Choice | 1 | 2018 | 744 | 0.400 |
Why?
|
Angioplasty, Balloon | 2 | 2008 | 653 | 0.400 |
Why?
|
Renal Insufficiency | 1 | 2016 | 804 | 0.360 |
Why?
|
Device Approval | 1 | 2012 | 163 | 0.360 |
Why?
|
Heart Diseases | 2 | 2014 | 2789 | 0.360 |
Why?
|
Biotechnology | 1 | 2012 | 281 | 0.350 |
Why?
|
Equipment and Supplies | 1 | 2012 | 281 | 0.340 |
Why?
|
Heart Valve Diseases | 1 | 2016 | 1074 | 0.320 |
Why?
|
Thoracic Surgery | 1 | 2014 | 719 | 0.300 |
Why?
|
Diabetic Angiopathies | 2 | 2010 | 818 | 0.300 |
Why?
|
Myocardial Ischemia | 3 | 2020 | 2148 | 0.290 |
Why?
|
Patient Selection | 2 | 2017 | 4216 | 0.290 |
Why?
|
Carotid Artery Diseases | 1 | 2013 | 879 | 0.280 |
Why?
|
Registries | 9 | 2014 | 8091 | 0.280 |
Why?
|
Education, Medical, Graduate | 1 | 2018 | 2291 | 0.270 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2016 | 1537 | 0.260 |
Why?
|
Clinical Trials as Topic | 4 | 2013 | 7914 | 0.220 |
Why?
|
Treatment Outcome | 16 | 2021 | 63107 | 0.220 |
Why?
|
Contrast Media | 1 | 2016 | 5300 | 0.220 |
Why?
|
Catheterization | 1 | 2008 | 1470 | 0.220 |
Why?
|
Prosthesis Design | 6 | 2016 | 2110 | 0.210 |
Why?
|
Coronary Vessels | 1 | 2014 | 3107 | 0.210 |
Why?
|
Cardiac Surgical Procedures | 2 | 2016 | 3537 | 0.200 |
Why?
|
Biomedical Research | 1 | 2016 | 3309 | 0.190 |
Why?
|
Diffusion of Innovation | 2 | 2016 | 725 | 0.170 |
Why?
|
Job Description | 1 | 2018 | 58 | 0.160 |
Why?
|
Stroke | 3 | 2015 | 9981 | 0.140 |
Why?
|
Sirolimus | 3 | 2010 | 1565 | 0.140 |
Why?
|
Furosemide | 1 | 2016 | 167 | 0.130 |
Why?
|
Coronary Angiography | 5 | 2020 | 4576 | 0.130 |
Why?
|
Humans | 33 | 2021 | 744366 | 0.120 |
Why?
|
Metals | 4 | 2012 | 719 | 0.120 |
Why?
|
Certification | 1 | 2018 | 423 | 0.120 |
Why?
|
Paclitaxel | 2 | 2010 | 1708 | 0.100 |
Why?
|
Forecasting | 2 | 2016 | 2951 | 0.100 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2012 | 187 | 0.100 |
Why?
|
Patents as Topic | 1 | 2012 | 103 | 0.100 |
Why?
|
Creatinine | 1 | 2016 | 1919 | 0.090 |
Why?
|
Europe | 3 | 2012 | 3338 | 0.090 |
Why?
|
Proportional Hazards Models | 6 | 2012 | 12356 | 0.090 |
Why?
|
Risk Assessment | 8 | 2017 | 23336 | 0.080 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3508 | 0.080 |
Why?
|
Risk Factors | 7 | 2017 | 72296 | 0.080 |
Why?
|
Severity of Illness Index | 6 | 2011 | 15535 | 0.080 |
Why?
|
United States | 11 | 2014 | 69872 | 0.080 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2012 | 430 | 0.080 |
Why?
|
Cardiovascular Diseases | 2 | 2020 | 15160 | 0.080 |
Why?
|
Government Regulation | 1 | 2012 | 522 | 0.070 |
Why?
|
Heart Valve Prosthesis | 1 | 2016 | 1490 | 0.070 |
Why?
|
Cardiovascular Agents | 2 | 2015 | 850 | 0.070 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2887 | 0.070 |
Why?
|
Hospital Mortality | 3 | 2012 | 5316 | 0.070 |
Why?
|
Time Factors | 7 | 2012 | 40075 | 0.070 |
Why?
|
Thrombosis | 4 | 2011 | 2968 | 0.060 |
Why?
|
Curriculum | 1 | 2018 | 3605 | 0.060 |
Why?
|
United States Food and Drug Administration | 1 | 2012 | 1584 | 0.060 |
Why?
|
Ventricular Function, Left | 1 | 2016 | 3666 | 0.060 |
Why?
|
Myocardial Infarction | 9 | 2011 | 11718 | 0.060 |
Why?
|
Diabetes Complications | 2 | 2008 | 1359 | 0.060 |
Why?
|
Comorbidity | 3 | 2012 | 10388 | 0.050 |
Why?
|
Thromboembolism | 1 | 2009 | 987 | 0.050 |
Why?
|
Education, Medical, Continuing | 1 | 2008 | 840 | 0.050 |
Why?
|
Clinical Competence | 1 | 2018 | 4687 | 0.050 |
Why?
|
Chronic Disease | 1 | 2017 | 9145 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 4 | 2020 | 6539 | 0.050 |
Why?
|
Canada | 2 | 2009 | 2065 | 0.050 |
Why?
|
Calcinosis | 1 | 2011 | 1499 | 0.050 |
Why?
|
Warfarin | 1 | 2009 | 1497 | 0.050 |
Why?
|
Female | 15 | 2020 | 380193 | 0.040 |
Why?
|
Follow-Up Studies | 3 | 2014 | 39052 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2002 | 780 | 0.040 |
Why?
|
Male | 14 | 2020 | 350115 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2002 | 1677 | 0.040 |
Why?
|
Middle Aged | 12 | 2020 | 213390 | 0.040 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2008 | 2104 | 0.030 |
Why?
|
Logistic Models | 3 | 2011 | 13409 | 0.030 |
Why?
|
Aged | 10 | 2020 | 163288 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2008 | 2873 | 0.030 |
Why?
|
Angina, Unstable | 1 | 2020 | 926 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2003 | 6896 | 0.030 |
Why?
|
Anticoagulants | 1 | 2009 | 4600 | 0.030 |
Why?
|
Insulin | 1 | 2008 | 6582 | 0.030 |
Why?
|
Diabetes Mellitus | 2 | 2008 | 5749 | 0.030 |
Why?
|
Reoperation | 1 | 2002 | 4201 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2013 | 57776 | 0.030 |
Why?
|
Animals | 2 | 2016 | 168768 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2020 | 2307 | 0.030 |
Why?
|
Prospective Studies | 6 | 2011 | 53290 | 0.020 |
Why?
|
Atherectomy, Coronary | 1 | 2011 | 148 | 0.020 |
Why?
|
Atrial Fibrillation | 1 | 2009 | 5035 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2003 | 4153 | 0.020 |
Why?
|
Cineangiography | 1 | 2009 | 124 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2002 | 12244 | 0.020 |
Why?
|
Coronary Thrombosis | 1 | 2011 | 495 | 0.020 |
Why?
|
Survival Rate | 1 | 2002 | 12788 | 0.020 |
Why?
|
Ultrasonography, Interventional | 2 | 2008 | 1486 | 0.020 |
Why?
|
New Zealand | 1 | 2008 | 355 | 0.020 |
Why?
|
Echocardiography, Doppler, Color | 1 | 2009 | 364 | 0.020 |
Why?
|
Product Labeling | 1 | 2008 | 79 | 0.020 |
Why?
|
Retreatment | 1 | 2008 | 610 | 0.020 |
Why?
|
Quality of Life | 2 | 2020 | 12802 | 0.020 |
Why?
|
Observation | 1 | 2008 | 312 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2002 | 9955 | 0.020 |
Why?
|
Atrial Appendage | 1 | 2009 | 283 | 0.020 |
Why?
|
Australia | 1 | 2008 | 1167 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2014 | 77460 | 0.020 |
Why?
|
Propensity Score | 1 | 2011 | 1781 | 0.010 |
Why?
|
Smoking | 2 | 2011 | 8987 | 0.010 |
Why?
|
Treatment Failure | 1 | 2009 | 2618 | 0.010 |
Why?
|
Echocardiography, Transesophageal | 1 | 2009 | 1133 | 0.010 |
Why?
|
Equipment Design | 1 | 2009 | 3582 | 0.010 |
Why?
|
Cohort Studies | 1 | 2002 | 40559 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2009 | 5077 | 0.010 |
Why?
|
Stroke Volume | 1 | 2011 | 5006 | 0.010 |
Why?
|
Sex Factors | 1 | 2011 | 10400 | 0.010 |
Why?
|
Survival Analysis | 1 | 2008 | 10252 | 0.010 |
Why?
|
Age Factors | 1 | 2011 | 18373 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2003 | 12025 | 0.010 |
Why?
|
Hypertension | 1 | 2008 | 8479 | 0.010 |
Why?
|
Adult | 1 | 2009 | 214052 | 0.000 |
Why?
|